Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 batch-consistency and immunogenicity bridging study of oral hexavalent reassortant rotavirus live vaccine in Chinese infants
ChiCTR2500097341Phase 3Completed
- Sponsor
- Hebei Provincial Center for Disease Prevention and Control
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oral hexavalent reassortant rotavirus attenuated live vaccine (Vero cell) in rotaviral diarrhea (4 arms), sponsored by Hebei Provincial Center for Disease Prevention and Control. Primary endpoint: Geometric mean concentrations and seroconversion rates of anti-rotavirus IgA. Started Feb 2025; status: completed.
02
Drugs
oral hexavalent reassortant rotavirus attenuated live vaccine (Vero cell)
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on ChiCTR2500097341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097341.